Items tagged with Diagnostics
An Activist's Guide to the TB LAM Test (post with simple image)
Treatment Action Group releases an updated version of its Activist’s Guide to the LAM Test with a complementary resource that tracks the status of LAM uptake in the 30 high TB/HIV burden countries.
TAG statement on the high price of Cepheid’s Xpert test for COVID-19 (post with simple image)
Cepheid is profiteering during a pandemic, with dangerous consequences for countries with vulnerable populations and health systems.
Civil society call for equitable and affordable access to COVID-19 and related diagnostics (post with simple image)
Advocates call for a higher level of global coordination, transparency, and accountability to ensure sustainable and equitable access to testing.
WHO urges countries to expand access to rapid molecular tests for the detection of TB and drug-resistant TB (post with simple image)
WHO releases updated guidelines for TB diagnosis, recommending rapid molecular tests as initial tests for TB detection.
TAG launches two new TB Activist Guides (post with simple image)
Treatment Action Group launches two new TB Activist Guides: An Activist’s Guide to Tuberculosis Diagnostic Tools, and An Activist’s Guide to Treatment for Drug-Resistant Tuberculosis.
TAG policy brief: Advancing Access through Market Interventions (post with simple image)
Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down
TAG's 2020 Pipeline Report: TB chapters released (post with simple image)
Treatment Action Group (TAG) launches newly available TB chapters of its 2020 Pipeline Report.
Advocates request Cepheid increase access to GeneXpert SARS-CoV-2 tests in LMICs (post with simple image)
Advocates demand Cepheid commit a greater proportion of its COVID-19 manufacturing capacity to LMICs and lower the price of its cartridges to $5.
TB testing in 2020 dropped drastically due to COVID-19 (post with simple image)
Global Fund surveys in 13 countries with the highest TB burden in the world reveal that 29% fewer people were tested for TB compared to 2019.
Time for $5 Coalition statement: Cepheid’s updated GeneXpert pricing does not address country needs (post with simple image)
The Time for $5 Coalition calls out Cepheid for not including price reductions of Xpert tests in their updated GeneXpert pricing packages for low- and middle-income countries.
Page 66 of 69 · Total posts: 0
←First 65 66 67 Last→